Information Provided By: 
Fly News Breaks for July 20, 2017
AEZS
Jul 20, 2017 | 07:56 EDT
Maxim analyst Jason Kolbert noted that that the FDA has set a December 30, 2017 PDUFA date for Aeterna Zentaris' Macrilen, which would be the only FDA-approved drug for the assessment of Adult Growth Hormone Deficiency if approved. The analyst, who sees Macrilen as poised to displace the Insulin Tolerance Test, raised his price target on Aeterna shares to $4 from $2 and keeps a Buy rating on the stock.
News For AEZS From the Last 2 Days
There are no results for your query AEZS
